DRMAW (STOCKS)

    Dermata Therapeutics, Inc. Warrant

    $0.019300
    +0.002000 (+11.56%)
    Prev close: $0.017300
    Company Information
    Exchange
    XNAS
    Sector
    Health Technology
    Industry
    Pharmaceuticals Major
    CEO
    Gerry Proehl, MBA
    Asset Type
    stocks
    Website
    Visit
    Fundamentals
    Market Cap
    Employees
    8
    P/E (TTM)
    P/B (TTM)
    Dividend Yield
    Technical Indicators
    SMA 10
    SMA 20
    SMA 50
    EMA 9
    EMA 21
    RSI
    MACD State
    Recent News

    No recent news found for this ticker.

    Financial Statements
    TTM (Sep 2025)
    Revenues $0.00
    Operating Expenses $9.07M
    Research and Development $4.60M
    Operating Income/Loss -$9.07M
    Income/Loss From Continuing Operations After Tax -$8.85M
    Income/Loss From Continuing Operations Before Tax -$8.85M
    Net Income/Loss -$8.85M
    Net Income/Loss Attributable To Noncontrolling Interest $0.00
    Net Income/Loss Attributable To Parent -$8.85M
    Net Income/Loss Available To Common Stockholders, Basic -$8.85M
    Participating Securities, Distributed And Undistributed Earnings/Loss, Basic $0.00
    Preferred Stock Dividends And Other Adjustments $0.00
    Basic Earnings Per Share $87.51
    Diluted Earnings Per Share $87.51
    Diluted Average Shares 2,298,373
    Assets $5.07M
    Current Assets $5.07M
    Noncurrent Assets $0.00
    Liabilities $1.11M
    Current Liabilities $1.11M
    Accounts Payable $453.43K
    Wages $594.14K
    Other Current Liabilities $63.74K
    Noncurrent Liabilities $0.00
    Equity $3.96M
    Equity Attributable To Noncontrolling Interest $0.00
    Equity Attributable To Parent $3.96M
    Liabilities And Equity $5.07M
    Net Cash Flow From Operating Activities -$9.28M
    Net Cash Flow From Operating Activities, Continuing -$9.28M
    Net Cash Flow From Investing Activities $12.58M
    Net Cash Flow From Investing Activities, Continuing $12.58M
    Net Cash Flow From Financing Activities $7.86M
    Net Cash Flow From Financing Activities, Continuing $7.86M
    Net Cash Flow -$11.10M
    Net Cash Flow, Continuing $2.90M
    Comprehensive Income/Loss -$8.85M
    Comprehensive Income/Loss Attributable To Noncontrolling Interest $0.00
    Comprehensive Income/Loss Attributable To Parent -$8.85M
    Other Comprehensive Income/Loss $0.00